<HTML xmlns="http://www.w3.org/TR/REC-html40" xmlns:v =
"urn:schemas-microsoft-com:vml" xmlns:o =
"urn:schemas-microsoft-com:office:office" xmlns:w =
"urn:schemas-microsoft-com:office:word" xmlns:m =
"http://schemas.microsoft.com/office/2004/12/omml"><HEAD>
<META content="text/html; charset=utf-8" http-equiv=Content-Type>
<META name=Generator content="Microsoft Word 12 (filtered medium)">
<STYLE>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</STYLE>
<STYLE><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:18.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;}
p.node, li.node, div.node
{mso-style-name:node;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></STYLE>
</HEAD>
<BODY lang=EN-CA dir=ltr link=blue vLink=purple>
<DIV dir=ltr>
<DIV style="FONT-SIZE: 14pt; FONT-FAMILY: 'Arial'; COLOR: #0000ff">
<DIV><FONT color=#ff0000 size=6>YES!!</FONT></DIV>
<DIV
style="FONT-SIZE: small; FONT-FAMILY: 'Calibri'; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal; TEXT-DECORATION: none; DISPLAY: inline">
<DIV style="FONT: 10pt tahoma">
<DIV> </DIV>
<DIV style="BACKGROUND: #f5f5f5">
<DIV style="font-color: black"><B>From:</B> <A title=glen.tolhurst@sympatico.ca
href="mailto:glen.tolhurst@sympatico.ca">Glen Tolhurst</A> </DIV>
<DIV><B>Sent:</B> Saturday, November 21, 2015 4:35 PM</DIV>
<DIV><B>To:</B> <A title=hopespringpcsg@artsservices.uwaterloo.ca
href="mailto:hopespringpcsg@artsservices.uwaterloo.ca">hopespringpcsg@artsservices.uwaterloo.ca</A>
</DIV>
<DIV><B>Cc:</B> <A title=jim079@sympatico.ca
href="mailto:jim079@sympatico.ca">jim079@sympatico.ca</A> ; <A
title=walter.eadie@cogeco.ca href="mailto:walter.eadie@cogeco.ca">'Walter
Eadie'</A> ; <A title=jfdorsey@yahoo.com href="mailto:jfdorsey@yahoo.com">Jim
Dorsey</A> </DIV>
<DIV><B>Subject:</B> [Hopespringpcsg] FW: FYI From webmd.com Topic:Prostate
CancerScreening, Detection Down in U.S.</DIV></DIV></DIV>
<DIV> </DIV></DIV>
<DIV
style="FONT-SIZE: small; FONT-FAMILY: 'Calibri'; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal; TEXT-DECORATION: none; DISPLAY: inline">
<DIV class=WordSection1>
<P class=MsoNormal><SPAN style="COLOR: #1f497d">Hi all:</SPAN></P>
<P class=MsoNormal><SPAN
style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; COLOR: #1f497d">Interesting
article.<o:p></o:p></SPAN></P>
<P class=MsoNormal><SPAN
style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; COLOR: #1f497d">Will
there be a spike in PCa in 5-10 years?<o:p></o:p></SPAN></P>
<P class=MsoNormal><SPAN
style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; COLOR: #1f497d">Take
care,<o:p></o:p></SPAN></P>
<P class=MsoNormal><SPAN
style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; COLOR: #1f497d">Glen<o:p></o:p></SPAN></P>
<DIV>
<DIV id=textArea>
<H2>Prostate Cancer Screening, Detection Down in U.S.<o:p></o:p></H2>
<DIV>
<P class=MsoNormal>But whether that's good or bad isn't yet
clear<o:p></o:p></P></DIV>
<DIV>
<P class=MsoNormal><BR>WebMD News from HealthDay<o:p></o:p></P></DIV>
<P class=node>By Amy Norton<o:p></o:p></P>
<P class=node><I>HealthDay Reporter</I> <o:p></o:p></P>
<P class=node>TUESDAY, Nov. 17, 2015 (HealthDay News) -- Fewer U.S. men are
being screened for <A
href="http://www.webmd.com/prostate-cancer/default.htm">prostate cancer</A>, and
fewer cases of the disease are being diagnosed nationwide, according to two
studies published Tuesday.<o:p></o:p></P>
<P class=node>The big question, researchers said, is whether that trend is bad
news or a step in the right direction.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>At issue is the prostate-specific antigen, or PSA, test. For years
in the United States, men age 50 and older routinely underwent PSA screening to
help detect early <A
href="http://www.webmd.com/prostate-cancer/ss/slideshow-prostate-cancer-overview">prostate
cancer</A>.<o:p></o:p></P>
<P class=node>But in 2012, the U.S. Preventive Services Task Force (USPSTF) -- a
panel that advises the federal government -- came out against routine PSA
screening.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>The panel cited evidence that screening might do more harm than
good: Prostate cancer is often slow-growing, and may never advance to the point
where it threatens a man's life. So men diagnosed with early prostate tumors
might needlessly be subjected to surgery, <A
href="http://www.webmd.com/cancer/what-to-expect-from-radiation-therapy">radiation</A>
and other treatments that can cause lingering side effects such as <A
href="http://www.webmd.com/erectile-dysfunction/default.htm">impotence</A> and
<A
href="http://www.webmd.com/urinary-incontinence-oab/default.htm">incontinence</A>,
the researchers said.<o:p></o:p></P>
<P class=node>The two new studies, published Nov. 17 in the <I>Journal of the
American Medical Association,</I> suggest that the USPSTF recommendations have
had an impact.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>In one study, researchers with the American <A
href="http://www.webmd.com/cancer/">Cancer</A> Society (ACS) found that in 2013,
31 percent of U.S. men age 50 and older said they'd had a PSA test in the past
year. That was down from 38 percent in 2010, and about 41 percent in 2008 -- the
year the USPSTF began advising against routine PSA testing for men ages 75 and
up.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>At the same time, diagnoses of prostate cancer declined nationwide
-- from more than 213,000 men in 2011, to about 180,000 in 2012.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>The second study, by researchers from Brigham and Women's Hospital
and Dana-Farber <A
href="http://www.webmd.com/cancer/ss/does-this-cause-cancer">Cancer</A>
Institute in Boston, and Henry Ford Health System in Detroit, looked only at
screening rates and found a similar pattern. The largest decline in PSA
screening was among men ages 60 to 64: In 2010, 45 percent underwent screening,
versus 35 percent in 2013. Men ages 50 to 54 also saw a big decline, with just
18 percent getting a PSA test in 2013 compared to 23 percent in
2010.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>"The decline in incidence and the decline in the proportion of men
getting screened likely means that doctors and patients are beginning to
understand that it's not known whether prostate cancer screening saves lives,"
said Dr. Otis Brawley, the chief medical officer for the ACS.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>On the other hand, Brawley said, it's clear that PSA screening can
do harm.<o:p></o:p></P>
<P class=node>"One of the things we do know," he said, "is that screening is
more likely to diagnose the kind of [prostate] cancer that is not a threat to
health and does not need treatment."<o:p></o:p></P>
<P class=node>There have been 11 <A
href="http://www.webmd.com/a-to-z-guides/clincial-trial-guide-patients">clinical
trials</A> testing the effects of PSA screening, Brawley said, and only two have
found benefits for men's lives. "But all 11 show harms associated with
screening," he added.<o:p></o:p></P>
<P class=node>Others, however, were more worried about the trends in the ACS
report.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>"This study raises a troubling suggestion that we may be missing
patients we want to find with screening," said Dr. Richard Greenberg, chief of
urologic oncology at Fox Chase Cancer Center, in Philadelphia.<o:p></o:p></P>
<P class=node>"Specifically, younger men who are currently not getting screened
may have cancer 10 years from now that is no longer curable," Greenberg
said.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>Dr. David Penson, a urologic surgeon at Vanderbilt University, in
Nashville, Tenn., also expressed concerns.<o:p></o:p></P>
<P class=node>"We don't know how this will all play out," said Penson, who wrote
an editorial published with the studies. "But I'd be willing to bet that this
will be followed by an increase in prostate cancer mortality."<o:p></o:p></P>
<P class=node>Penson agreed that in years past, PSA screening was probably
overused. But the pendulum may be swinging too far in the other direction, he
said.<o:p></o:p></P>
<P class=node>"I would argue that we need to land somewhere in between," he
said.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>What's needed, according to Penson, is more research to better
define which men are higher-risk and could benefit from more-intensive PSA
screening. He pointed to one study from Sweden that found that a man's PSA level
in his late 40s might help predict his risk of developing prostate cancer later
in life.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>That raises the possibility that a single PSA measurement at a
relatively young age could help doctors figure out when and how often to do
further testing, according to Penson.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>Another way to address the issue is to further reduce
"overtreatment" of prostate cancer. Men diagnosed with small, nonaggressive
tumors do not have to be treated right away, Penson pointed out.<o:p></o:p></P>
<P class=node>"They can opt for active surveillance," he said. "More and more
men with low-risk prostate cancer are doing that."<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>Active surveillance means that a man's cancer is monitored over
time, using PSA tests and possibly <A
href="http://www.webmd.com/cancer/what-is-a-biopsy">biopsies</A> of the
tumor.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>For now, all three experts suggested that men talk with their
doctors about the benefits and risks of PSA screening.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>"I do hope physicians are talking to their patients and letting
the patient decide whether or not to be screened," Brawley said.<o:p></o:p></P>
<P class=node><o:p></o:p> </P>
<P class=node>For most men that discussion should begin at age 50, according to
the American Cancer Society.<o:p></o:p></P>
<P class=node>But men at increased risk should talk to their doctors starting at
age 45, Brawley said. That includes black men and those with a brother or father
who developed prostate cancer before the age of 65, according to the American
Cancer Society.<o:p></o:p></P>
<DIV>
<DIV>
<DIV>
<P class=MsoNormal><A
href="http://www.webmd.com/men/news/20151117/prostate-cancer-screening-detection-both-down-in-us-studies-say?page=3">View
Article Sources <SPAN style="TEXT-DECORATION: none"><IMG id=sources_sign_fmt
border=0 alt=Sources
src="http://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/modules/todaysNews_plusSign.gif"></SPAN></A><o:p></o:p></P></DIV></DIV>
<DIV>
<P class=MsoNormal><IMG id=_x0000_i1026 border=0 alt=HealthDay
src="http://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/logos/vendor/healthday_logo_81x25.jpg"
width=81 height=25><BR>Copyright © 2013-2015 HealthDay. All rights
reserved.<BR><BR><BR><BR><A
href="url:http://www.webmd.com/men/news/20151117/prostate-cancer-screening-detection-both-down-in-us-studies-say">url:http://www.webmd.com/men/news/20151117/prostate-cancer-screening-detection-both-down-in-us-studies-say</A><o:p></o:p></P></DIV></DIV></DIV></DIV>
<P class=MsoNormal>-- <BR>You received this message because you are subscribed
to the Google Groups "FYI Prostate Info" group.<BR>To unsubscribe from this
group and stop receiving emails from it, send an email to <A
href="mailto:fyi-prostate-info+unsubscribe@googlegroups.com">fyi-prostate-info+unsubscribe@googlegroups.com</A>.<BR>To
post to this group, send email to <A
href="mailto:fyi-prostate-info@googlegroups.com">fyi-prostate-info@googlegroups.com</A>.<BR>To
view this discussion on the web visit <A
href="https://groups.google.com/d/msgid/fyi-prostate-info/0530454e-ccfe-4ee8-b421-89fac119117b%40googlegroups.com?utm_medium=email&utm_source=footer">https://groups.google.com/d/msgid/fyi-prostate-info/0530454e-ccfe-4ee8-b421-89fac119117b%40googlegroups.com</A>.<BR>For
more options, visit <A
href="https://groups.google.com/d/optout">https://groups.google.com/d/optout</A>.<o:p></o:p></P></DIV>
<P>
<HR>
_______________________________________________<BR>Hopespringpcsg mailing
list<BR>Hopespringpcsg@artslist.uwaterloo.ca<BR>To Subscribe or Unsubscribe
visit:<BR>https://artsservices.uwaterloo.ca/mailman/listinfo/hopespringpcsg<BR></DIV></DIV></DIV></BODY></HTML>